(WASHINGTON) — After battling breast cancer in 2008, Lisbeth Ceriani took on a whole new challenge. She joined a lawsuit against a biotechnology company she believed was blocking her ability to make informed decisions about her ongoing treatment.
Myriad Genetics was awarded patents in the 1990s on two isolated genes called BRCA 1 and BRCA2 as well as diagnostic methods. Women with mutations in those genes are at a much higher risk for breast and ovarian cancer. Because of the patent, Myriad is the only place to go for testing, and it sets the $3,340 price tag.
Ceriani’s problem was that even though her doctors recommended she get the test to make an informed decision about future risks — ovarian cancer in particular — she could not afford it. She was stunned to learn that the patents give Myriad the right to prevent others from doing commercial testing.
“I think my genes are mine,” she says. “Myriad thinks they are not mine.”
On Monday, the Supreme Court will hear a challenge to Myriad’s patents originally brought by scientists, researchers and patients who believe the patents stand in the way of further research on the genes and limit the availability of testing. The American Civil Liberties Union is representing the groups and argues that the Court should invalidate the patents because they cover a product of nature and not an actual invention.
The case has huge ramifications for biotechnology companies racing to create personalized tests and treatments tailored to a person’s genetic make-up.
Myriad says that the patents have been essential to the development of diagnostic tools to help patients and doctors assess the risks of cancer. The company rejects the notion that it somehow owns someone’s genes.
“Each individual’s DNA is theirs,” says Mark Capone, the company’s president. He says that what his scientists did was identify, define and isolate the genes out of the human body, which led to a momentous scientific advancement.
The company says it spent over $500 million and that it took 17 years to recoup the capital investment. Without protection from a strong patent system, Myriad argues it won’t have the incentive to charge ahead.
Capone says over one million women have been tested and that 95 percent of patients in the U.S. have access to the testing through private insurance and other coverage.
Copyright 2013 ABC News Radio
Natalia Hepworth, EastIdahoNews.com
Carina Storrs Special to CNN
Sarah Stewart, KFOR